|
EP2802576B1
(en)
|
2012-01-13 |
2018-06-27 |
Bristol-Myers Squibb Company |
Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
|
|
CN104254533B
(zh)
*
|
2012-01-13 |
2017-09-08 |
百时美施贵宝公司 |
用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物
|
|
WO2014058685A1
(en)
|
2012-10-08 |
2014-04-17 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
|
KR20150079963A
(ko)
|
2012-11-08 |
2015-07-08 |
브리스톨-마이어스 스큅 컴퍼니 |
키나제 조절제로서 유용한 헤테로아릴 치환된 피리딜 화합물
|
|
CN104781251B
(zh)
*
|
2012-11-08 |
2016-12-14 |
百时美施贵宝公司 |
可作为激酶调节剂的经双环杂环取代的吡啶基化合物
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
TWI667233B
(zh)
|
2013-12-19 |
2019-08-01 |
德商拜耳製藥公司 |
新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
|
|
TW201609693A
(zh)
|
2014-01-03 |
2016-03-16 |
必治妥美雅史谷比公司 |
雜芳基取代之菸鹼醯胺化合物
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
DK3300500T3
(da)
|
2015-05-20 |
2020-05-18 |
Amgen Inc |
Triazolagonister af apj-receptoren
|
|
WO2016210036A1
(en)
|
2015-06-24 |
2016-12-29 |
Bristol-Myers Squibb Company |
Heteroaryl substituted aminopyridine compounds
|
|
ES2822956T3
(es)
*
|
2015-06-24 |
2021-05-05 |
Bristol Myers Squibb Co |
Compuestos de aminopiridina sustituidos con heteroarilo
|
|
TW201718571A
(zh)
|
2015-06-24 |
2017-06-01 |
必治妥美雅史谷比公司 |
經雜芳基取代之胺基吡啶化合物
|
|
WO2017192485A1
(en)
|
2016-05-03 |
2017-11-09 |
Amgen Inc. |
Heterocyclic triazole compounds as agonists of the apj receptor
|
|
CN106222183B
(zh)
*
|
2016-07-25 |
2019-11-08 |
南通大学 |
靶向人irak1基因的小干扰rna及其应用
|
|
EP3848370B1
(en)
*
|
2016-10-14 |
2025-05-07 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors and uses thereof
|
|
WO2018093579A1
(en)
|
2016-11-16 |
2018-05-24 |
Amgen Inc. |
Triazole phenyl compounds as agonists of the apj receptor
|
|
US11020395B2
(en)
|
2016-11-16 |
2021-06-01 |
Amgen Inc. |
Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
|
|
EP3541792B1
(en)
|
2016-11-16 |
2020-12-23 |
Amgen Inc. |
Triazole furan compounds as agonists of the apj receptor
|
|
EP3541803B1
(en)
|
2016-11-16 |
2020-12-23 |
Amgen Inc. |
Triazole pyridyl compounds as agonists of the apj receptor
|
|
US11046680B1
(en)
|
2016-11-16 |
2021-06-29 |
Amgen Inc. |
Heteroaryl-substituted triazoles as APJ receptor agonists
|
|
WO2018093576A1
(en)
|
2016-11-16 |
2018-05-24 |
Amgen Inc. |
Alkyl substituted triazole compounds as agonists of the apj receptor
|
|
TW202340194A
(zh)
|
2017-02-16 |
2023-10-16 |
美商基利科學股份有限公司 |
吡咯并[1,2-b]嗒𠯤衍生物
|
|
PE20191817A1
(es)
|
2017-05-11 |
2019-12-27 |
Bristol Myers Squibb Co |
Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4)
|
|
MX2020003190A
(es)
|
2017-09-22 |
2020-11-11 |
Kymera Therapeutics Inc |
Degradadores de proteinas y usos de los mismos.
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
US11149040B2
(en)
|
2017-11-03 |
2021-10-19 |
Amgen Inc. |
Fused triazole agonists of the APJ receptor
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
WO2019111218A1
(en)
|
2017-12-08 |
2019-06-13 |
Cadila Healthcare Limited |
Novel heterocyclic compounds as irak4 inhibitors
|
|
EP3728228A1
(en)
|
2017-12-22 |
2020-10-28 |
Ravenna Pharmaceuticals, Inc. |
Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
CN110317190A
(zh)
*
|
2018-03-28 |
2019-10-11 |
首都医科大学 |
一种三唑-羧酸酯类衍生物在医药领域的应用
|
|
WO2019213006A1
(en)
|
2018-05-01 |
2019-11-07 |
Amgen Inc. |
Substituted pyrimidinones as agonists of the apj receptor
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
TWI842978B
(zh)
*
|
2018-07-13 |
2024-05-21 |
美商基利科學股份有限公司 |
衍生物
|
|
JP7623943B2
(ja)
|
2018-11-30 |
2025-01-29 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ分解剤およびそれらの使用
|
|
TW202112767A
(zh)
|
2019-06-17 |
2021-04-01 |
美商佩特拉製藥公司 |
作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
|
|
BR112021026517A2
(pt)
|
2019-06-28 |
2022-05-10 |
Kymera Therapeutics Inc |
Degradadores de irak e usos dos mesmos
|
|
WO2021011868A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
CN114127075B
(zh)
|
2019-07-18 |
2024-05-14 |
百时美施贵宝公司 |
可用作IRAK4抑制剂的吡唑并[3,4-d]吡咯并[1,2-b]哒嗪基化合物
|
|
EP3999508B1
(en)
|
2019-07-18 |
2023-08-30 |
Bristol-Myers Squibb Company |
Tricyclic heteroaryl compounds useful as irak4 inhibitors
|
|
JP7573596B2
(ja)
|
2019-07-23 |
2024-10-25 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物
|
|
WO2021026181A1
(en)
|
2019-08-06 |
2021-02-11 |
Bristol-Myers Squibb Company |
Bicyclic heterocyclic compounds useful as irak4 inhibitors
|
|
ES3059914T3
(en)
|
2019-08-13 |
2026-03-24 |
Bristol Myers Squibb Co |
Bicyclic heteroaryl compounds useful as irak4 inhibitors
|
|
US12551564B2
(en)
|
2019-12-10 |
2026-02-17 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
WO2021127190A1
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021158495A1
(en)
|
2020-02-03 |
2021-08-12 |
Bristol-Myers Squibb Company |
Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors
|
|
EP4100408B1
(en)
|
2020-02-03 |
2024-02-28 |
Bristol-Myers Squibb Company |
Tricyclic heteroaryl compounds useful as irak4 inhibitors
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
MX2023003698A
(es)
*
|
2020-09-30 |
2023-06-15 |
Asahi Kasei Pharma Corp |
Compuesto biciclico que contiene nitrogeno y pirimidina.
|
|
PH12023500015A1
(en)
|
2020-12-30 |
2024-03-11 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2022174268A1
(en)
|
2021-02-15 |
2022-08-18 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
AU2022271290A1
(en)
|
2021-05-07 |
2023-11-23 |
Kymera Therapeutics, Inc. |
Cdk2 degraders and uses thereof
|
|
US12187744B2
(en)
|
2021-10-29 |
2025-01-07 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and synthesis thereof
|
|
EP4472967A4
(en)
|
2022-01-31 |
2026-04-15 |
Kymera Therapeutics Inc |
Iraqi Degradation Agents and Their Uses
|
|
WO2026005537A1
(ko)
*
|
2024-06-28 |
2026-01-02 |
주식회사 대웅제약 |
신규한 화합물, 및 이를 포함하는 암 또는 자가 면역 질환의 예방 또는 치료용 약학적 조성물
|